GlassScriptPhysician profile
Michael D Moore
NPI 1366521759
$3,595.45
in general payments reported to CMS, 2019-2025
19 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $251 · 2021: $306 · 2022: $825 · 2023: $426 · 2024: $957 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $523.55 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $507.54 | 2023-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Alcon Vision LLC | $485.25 | 2022-2025 | Rocklatan, Simbrinza |
| Novartis Pharmaceuticals Corporation | $248.18 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $236.75 | 2019-2021 | |
| Allergan, INC. | $214.65 | 2019-2021 | |
| Abbvie INC. | $210.94 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $173.25 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $159.93 | 2022-2023 | Flarex |
| Kala Pharmaceuticals, INC. | $157.88 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $128.84 | 2019-2021 | |
| Horizon Therapeutics Plc | $104.32 | 2022 | |
| Sun Pharmaceutical Industries INC. | $104.09 | 2022-2025 | |
| Thea Pharma INC. | $82.40 | 2023-2024 | Iyuzeh |
| Amgen INC. | $75.36 | 2025 | Tepezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $67.37 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $57.90 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $39.80 | 2023 | |
| Harrow Eye, LLC | $17.45 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.